{
  "documents": [
    {
      "id": "cluster_0_doc0",
      "content": "A recent audit of Mountain View Regional Hospital revealed increased telehealth utilization among rheumatology patients aged 45-60 since Q3 2023. The report flags inconsistent billing codes for combined physiotherapy sessions, particularly those involving patients with rare connective tissue disorders. Dr. Elena Kovac's department shows a 40% increase in prior authorization requests for specialized biologics.",
      "metadata": {
        "format": "audit_report"
      }
    },
    {
      "id": "cluster_0_doc1",
      "content": "Patient #77382 (52 y/o) received approval for off-label IVIG treatment following three peer-reviewed studies showing efficacy in refractory autoimmune cases. Treatment schedule coordinated through Valley Specialty Pharmacy includes biweekly infusions at coordinates 37.4085° N, 122.1450° W, with post-infusion monitoring required per new network guidelines.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_0_doc2",
      "content": "Effective November 1st, Blue Cross updated coverage criteria for rheumatology biologics based on genomic markers. All claims involving patients with baseline CRP >10 mg/L require additional documentation from treating physicians. Network pharmacies must use verification code RHEUM-2023 when dispensing these medications.",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_0_doc3",
      "content": "The Quarterly Journal of Autoimmunology published findings showing 62% response rate to combinational immunosuppressants in patients with overlapping Sjögren's and CREST syndromes. Study led by the Palo Alto Medical Foundation tracked outcomes using mobile symptom tracking system SynchroHealth v2.3.",
      "metadata": {
        "format": "research_note"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_0",
    "cluster_risk": "MEDIUM",
    "content_summary": "Rheumatology treatment innovations and policy changes centered around autoimmune therapies at Mountain View Regional & Palo Alto networks",
    "person": {
      "entities": [
        [
          "77382",
          "PATIENT_ID"
        ],
        [
          "52",
          "AGE"
        ],
        [
          "refractory autoimmune",
          "MEDICAL_CONDITION"
        ],
        [
          "biweekly infusions",
          "TREATMENT"
        ],
        [
          "Valley Specialty Pharmacy",
          "PROVIDER"
        ],
        [
          "37.4085° N, 122.1450° W",
          "LOCATION"
        ],
        [
          "Sjögren's",
          "MEDICAL_CONDITION"
        ],
        [
          "CREST",
          "MEDICAL_CONDITION"
        ],
        [
          "off-label IVIG treatment",
          "TREATMENT"
        ],
        [
          "post-infusion monitoring",
          "TREATMENT"
        ]
      ]
    },
    "questions": [
      {
        "q": "What infusion treatment frequency was approved for patient #77382 at Valley Specialty Pharmacy?",
        "a": "Biweekly infusions with post-infusion monitoring.",
        "sources": [
          "cluster_0_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "What genomic marker threshold triggers additional documentation for rheumatology biologics per November policy?",
        "a": "Baseline CRP levels above 10 mg/L.",
        "sources": [
          "cluster_0_doc2"
        ],
        "type": "general"
      },
      {
        "q": "Which two medical conditions does the SynchroHealth study target, and what infusion treatment frequency was approved for patient #77382 at Valley Specialty Pharmacy?",
        "a": "Sjögren's syndrome, CREST syndrome; biweekly infusions.",
        "sources": [
          "cluster_0_doc1",
          "cluster_0_doc3"
        ],
        "type": "specific"
      },
      {
        "q": "What two changes occurred at Mountain View Regional regarding rheumatology care in Q3, and what verification code is required for dispensing biologics?",
        "a": "40% increase in prior authorizations, inconsistent billing codes; RHEUM-2023 verification code.",
        "sources": [
          "cluster_0_doc0",
          "cluster_0_doc2"
        ],
        "type": "general"
      }
    ]
  }
}